88 related articles for article (PubMed ID: 20811663)
21. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
23. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
24. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract][Full Text] [Related]
25. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene.
Ide F; Kitada M; Sakashita H; Kusama K; Tanaka K; Ishikawa T
Am J Pathol; 2003 Nov; 163(5):1729-33. PubMed ID: 14578172
[TBL] [Abstract][Full Text] [Related]
26. Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma.
Nakatani K; Nakamura M; Uzawa K; Wada T; Seki N; Tanzawa H; Fujita S
Oncol Rep; 2005 Apr; 13(4):709-14. PubMed ID: 15756446
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity.
Chiba I; Shindoh M; Yasuda M; Yamazaki Y; Amemiya A; Sato Y; Fujinaga K; Notani K; Fukuda H
Oncogene; 1996 Apr; 12(8):1663-8. PubMed ID: 8622886
[TBL] [Abstract][Full Text] [Related]
28. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
29. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function.
Dorigo O; Turla ST; Lebedeva S; Gjerset RA
J Neurosurg; 1998 Mar; 88(3):535-40. PubMed ID: 9488309
[TBL] [Abstract][Full Text] [Related]
30. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
31. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
Pratesi G; Perego P; Polizzi D; Righetti SC; Supino R; Caserini C; Manzotti C; Giuliani FC; Pezzoni G; Tognella S; Spinelli S; Farrell N; Zunino F
Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
[TBL] [Abstract][Full Text] [Related]
32. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
[TBL] [Abstract][Full Text] [Related]
33. The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma.
Zhang B; Liu M; Tang HK; Ma HB; Wang C; Chen X; Huang HZ
J Oral Pathol Med; 2012 Feb; 41(2):141-8. PubMed ID: 21793937
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells.
Jung M; Notario V; Dritschilo A
Cancer Res; 1992 Nov; 52(22):6390-3. PubMed ID: 1423286
[TBL] [Abstract][Full Text] [Related]
35. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Temam S; Flahault A; Périé S; Monceaux G; Coulet F; Callard P; Bernaudin JF; St Guily JL; Fouret P
J Clin Oncol; 2000 Jan; 18(2):385-94. PubMed ID: 10637254
[TBL] [Abstract][Full Text] [Related]
36. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of the response of esophageal carcinoma cells to cisplatin.
Takashima N; Ishiguro H; Kuwabara Y; Kimura M; Mitui A; Mori Y; Mori R; Tomoda K; Hamaguchi M; Ogawa R; Katada T; Harada K; Fujii Y
Dis Esophagus; 2008; 21(3):230-5. PubMed ID: 18430104
[TBL] [Abstract][Full Text] [Related]
38. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
39. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Nakajima T; Yasufuku K; Nakagawara A; Kimura H; Yoshino I
Chest; 2011 Nov; 140(5):1319-1324. PubMed ID: 21527506
[TBL] [Abstract][Full Text] [Related]
40. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
Zhang P; Zhang Z; Zhou X; Qiu W; Chen F; Chen W
BMC Cancer; 2006 Sep; 6():224. PubMed ID: 16978399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
